Another milestone in the evolution of GLP-1-based diabetes therapies
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Native GLP-1 requires structural modification to resist rapid proteolytic degradation by dipeptidyl peptidase 4 (DPP-4).
“Pharmacological application of native GLP-1 requires modification to its structure to resist rapid proteolytic degradation by dipeptidyl peptidase 4 (DPP-4), a ubiquitous enzyme that is found in multiple organ beds.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [18]
Cites
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Self-citationSemaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · see citing works
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 611 · see citing works
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · see citing works
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works
Self-citationMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262 · see citing works
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254 · see citing works
Self-citationStructural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · see citing works
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156 · see citing works
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · see citing works
Structure‐function analysis of a series of glucagon‐like peptide‐1 analogs
Parker, J. C., Andrews, K. M., Rescek, D. M., Massefski, W. W., Andrews, G. C., Contillo, L. G., Stevenson, R. W., Singleton, D. H., & SULESKE, R. T. (1998) · Journal of Peptide Research · doi:10.1111/j.1399-3011.1998.tb00664.x · Cited by 41 · see citing works
Nauck, M. A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154031 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263 · see citing works
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158 · see citing works
The Expanding Role of GLP-1: From Diabetes Management to Cancer Treatment
Fareed, A., & Hussain, A. (2023) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514231213566 · Cited by 12 · see citing works
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 9 · see citing works
Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases
Ren, H., Yu, X., Li, M., Luo, Z., Lin, Y., Meng, Y., Cheng, Q., & Wei, T. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03184 · Cited by 4 · see citing works
Han, J. W., Han, N. R., Hwang, H. J., Lee, B. M., Shin, H. S., Lee, S. H., & Yang, Y. J. (2024) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-024-00146-x · Cited by 2 · see citing works
Fat – pharmacological therapies
Bain, S. C. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.367 · Cited by 2 · see citing works
- Authors
- Nauck, M. A., Quast, D. R., & Meier, J. J.
- Affiliations
- St. Josef-Hospital (DE)
- Augusta-Kranken-Anstalt (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Nature Medicine
- Published
- 2021-06
- Volume
- 27
- Issue
- 6
- Pages
- 952-953
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3172883297
- Cited by
- 7
- References
- 12
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, diabetes treatment
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
